Business Description
Werewolf Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing novel therapies that activate the body's immune system to combat cancer. Leveraging its exclusive PREDATOR platform, the company crafts conditionally activated molecules designed to stimulate both adaptive and innate immunity. This strategic approach aims to circumvent the shortcomings often associated with traditional proinflammatory immune treatments. Key among its product pipeline are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule targeting advanced solid tumors, and WTX-330, an Interleukin-12 INDUKINE molecule also designed for conditional activation, intended for advanced or metastatic solid tumors or lymphomas that have relapsed or are refractory. Furthermore, Werewolf Therapeutics is progressing WTX-613, a conditionally activated interferon alpha INDUKINE molecule, for addressing solid tumors and hematologic malignancies. The company was founded in 2017 and operates from its headquarters in Cambridge, Massachusetts.
Business History
Price Overview
Last updated: Jun 30, 2026 9:35pm (just now)Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): -1.32
Total Equity: $24.81M
Shares: 46,810,252
Total Debt: $1.75M
Cash: $57.95M
EBITDA: -$53.91M
Total Debt: $1.75M
Cash: $57.95M
Revenue: $0.00
Shares: 46,810,252
Revenue: $0.00
Revenue: $0.00
Revenue: $0.00
Total Equity: $24.81M
Tax Rate: 0.0%
Equity: $24.81M
Total Debt: $1.75M
Cash: $57.95M
Current Liabilities: $36.15M
Long-Term Debt: $0.00
Total Debt: $1.75M
Total Equity: $24.81M
Shares: 46,810,252
Shares: 46,810,252
CapEx: $0.00
Shares: 46,810,252
Stock Price: $0.36
Net Income: -$60.82M
Industry Benchmarks
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
Income Statement (Annual)
Last updated: Jun 30, 2026 9:35pm (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $16.4M | $19.9M | $1.9M | $0 |
| Cost of Revenue | $0 | $2.5M | $1.8M | $1.8M | $1.6M |
| Gross Profit | $0 | $13.9M | $18.2M | $71,000 | -$1.6M |
| Operating Expenses | $50.1M | $69.9M | $58.7M | $73.7M | $59.0M |
| Operating Income | -$50.1M | -$56.1M | -$40.5M | -$73.6M | -$60.7M |
| Net Income | -$50.0M | -$53.8M | -$37.4M | -$70.5M | -$60.8M |
| EBITDA | -$49.8M | -$51.3M | -$32.5M | -$64.0M | -$53.9M |
| EPS | $-10.94 | $-1.86 | $-1.05 | $-1.63 | $-1.32 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 30, 2026 9:35pm (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $157.5M | $129.3M | $134.3M | $111.0M | $58.0M |
| Total Current Assets | $161.1M | $140.2M | $138.4M | $113.1M | $58.6M |
| Total Assets | $179.3M | $160.2M | $174.8M | $126.9M | $69.4M |
| Current Liabilities | $11.9M | $24.0M | $19.4M | $15.2M | $36.1M |
| Long-Term Debt | $0 | $0 | $32.7M | $26.1M | $0 |
| Total Liabilities | $26.5M | $37.9M | $63.5M | $53.5M | $44.6M |
| Total Equity | $152.8M | $122.3M | $111.4M | $73.4M | $24.8M |
| Retained Earnings | -$252.9M | -$306.7M | -$344.1M | -$414.6M | -$475.4M |
Cash Flow (Annual)
Last updated: Jun 30, 2026 9:35pm (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$42.9M | -$40.6M | -$32.6M | -$56.2M | -$60.3M |
| Capital Expenditure | $-498,000 | -$3.6M | $-769,000 | $-254,000 | $0 |
| Free Cash Flow | -$43.4M | -$44.2M | -$33.4M | -$56.4M | -$60.3M |
| Acquisitions (net) | $0 | $0 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $66.1M | -$28.3M | $25.0M | -$43.4M | -$54.3M |
Analyst Estimates (Annual)
Last updated: Jun 30, 2026 9:35pm (just now)| Metric | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|
| Revenue |
$8.3M $8.3M – $8.3M
|
$3.1M $3.1M – $3.1M
|
$50,000 $50,000 – $50,000
|
$18.0M $18.0M – $18.0M
|
| EBITDA |
-$1.7M -$1.7M – -$1.7M
|
$-619,999 $-619,999 – $-619,999
|
$-9,999 $-9,999 – $-9,999
|
-$3.6M -$3.6M – -$3.6M
|
| Net Income |
-$46.4M -$49.0M – -$34.3M
|
-$74.7M -$74.7M – -$74.7M
|
-$68.8M -$68.8M – -$68.8M
|
-$46.1M -$46.1M – -$46.1M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 30, 2026 9:35pm (just now)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | — | +21.6% | -90.5% | -100.0% |
| Gross Profit Growth | — | +30.9% | -99.6% | -2,401.4% |
| Operating Income Growth | -11.9% | +27.7% | -81.7% | +17.6% |
| Net Income Growth | -7.7% | +30.6% | -88.7% | +13.7% |
| EBITDA Growth | -3.1% | +36.7% | -97.3% | +15.8% |
Insider Trading (Recent)
All SEC Form 4 codes
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-06-29 | EVNIN LUKE | S-Sale | 157,084.00 | $0.30 | $47,125 |
| 2026-06-17 | RA CAPITAL MANAGEMENT, L.P. | S-Sale | 389,216.00 | $0.35 | $136,226 |
| 2026-06-17 | RA CAPITAL MANAGEMENT, L.P. | S-Sale | 27,695.00 | $0.35 | $9,693 |
| 2026-06-12 | RA CAPITAL MANAGEMENT, L.P. | S-Sale | 159,119.00 | $0.40 | $63,648 |
| 2026-06-15 | RA CAPITAL MANAGEMENT, L.P. | S-Sale | 120,216.00 | $0.39 | $46,884 |
| 2026-06-16 | RA CAPITAL MANAGEMENT, L.P. | S-Sale | 139,686.00 | $0.37 | $51,684 |
| 2026-06-12 | RA CAPITAL MANAGEMENT, L.P. | S-Sale | 11,322.00 | $0.40 | $4,529 |
| 2026-06-15 | RA CAPITAL MANAGEMENT, L.P. | S-Sale | 8,554.00 | $0.39 | $3,336 |
| 2026-06-16 | RA CAPITAL MANAGEMENT, L.P. | S-Sale | 9,939.00 | $0.37 | $3,677 |
| 2026-06-09 | RA CAPITAL MANAGEMENT, L.P. | S-Sale | 345,235.00 | $0.37 | $127,737 |
| 2026-06-10 | RA CAPITAL MANAGEMENT, L.P. | S-Sale | 42,872.00 | $0.37 | $15,863 |
| 2026-06-11 | RA CAPITAL MANAGEMENT, L.P. | S-Sale | 245,066.00 | $0.38 | $93,125 |
| 2026-06-09 | RA CAPITAL MANAGEMENT, L.P. | S-Sale | 24,565.00 | $0.37 | $9,089 |
| 2026-06-10 | RA CAPITAL MANAGEMENT, L.P. | S-Sale | 3,051.00 | $0.37 | $1,129 |
| 2026-06-11 | RA CAPITAL MANAGEMENT, L.P. | S-Sale | 17,437.00 | $0.38 | $6,626 |
| 2026-06-09 | EVNIN LUKE | S-Sale | 76,928.00 | $0.37 | $28,463 |
| 2026-06-04 | EVNIN LUKE | S-Sale | 20,072.00 | $0.44 | $8,832 |
| 2026-06-05 | EVNIN LUKE | S-Sale | 24,946.00 | $0.40 | $9,978 |
| 2026-06-08 | EVNIN LUKE | S-Sale | 60,547.00 | $0.40 | $24,219 |
| 2026-06-01 | EVNIN LUKE | S-Sale | 80,459.00 | $0.47 | $37,816 |
Narrative Economics
market-narrative step).